Robust Specialty Pipeline Indicates Increased Competition for Certain Therapies

UBC understands increasing demands and competition in specialty market

Robust Specialty Pipeline Indicates Increased Competition for Certain Therapies

As the number of specialty drugs approved each year continues to rise, so does competition for market space within certain disease states, including cancer and hepatitis C.  The latest issue of Specialty Pharmacy Times includes a detailed listing of products slated for review by the FDA. 

UBC and our specialty pharmacy and specialty distribution partners, Accredo and CuraScript, understand the increasing demands and competition within the specialty market, and we are uniquely positioned to seamlessly integrate services to support specialty therapies throughout their lifecycle. 

To learn more, contact Kevin Cast, VP, Global Pharmaceutical Development.